Introduction
The MAP kinases (also called extracellular signalregulated kinases (ERK)) are serine/threonine kinases which are activated by many cytoplasmic signals that in¯uence cell proliferation and dierentiation (Blumer et al., 1994; Boulton et al., 1991; Cobb et al., 1991 Cobb et al., , 1994 Davis, 1993; Nishida and Gotoh, 1993; Ray and Sturgill, 1987; Seger and Krebs, 1995; Thomas, 1992) . ERKs are activated by phosphorylation by a speci®c group of enzymes, MAP kinase/ERK-kinases (MEKs) (Crews et al., 1992) . MEKs are dual speci®city protein kinases, which phosphorylate both a threonine and a tyrosine residue in ERKs (Nakielny et al., 1992) . Five isoforms of MEK have been cloned, which show a high degree of homology (Seger and Krebs, 1995) . Two isoforms of human MEK have been described (Zheng and Guan, 1993) .
Much work has indicated that mutations in dominant and recessive oncogenes are responsible for the pathogenesis of human lung cancer and at least some of the components of the MAP kinase pathway are mutated or have deranged expression in lung cancer cells including Her-2/neu, ras and c-myc Little et al., 1983; Minna, 1993 Minna, , 1994 Minna et al., 1997; Mitsudomi et al., 1991) . In addition several studies have indicated that lung cancer cells produce and respond to autocrine and paracrine growth factors, suggesting a possible role for these factors or their receptors in lung cancer growth (Minna, 1993) . Thus, constitutive activation of components of the MAP kinase cascade due to genetic changes would activate other regulatory molecules in the signaling pathway leading to the induction of cell growth and generation of a malignant cell.
Mansour and colleagues designed constitutively active mutants of MEK-1 by deleting N-terminal amino acids 32 ± 51 as well as changing regulatory phosphorylated serines (residues 218 and 222) to glutamic acid (Mansour et al., 1994) . The resulting protein had 400-fold higher basal activity than the wild type unphosphorylated MEK. Expression of these mutants in mammalian cells lead to activation of AP-1-regulated transcription, cellular transformation and solid tumor growth in nude mice. Similarly, Cowley et al. (1994) generated constitutively activated and interfering mutants of MEK-1, by changing the same serine residues 218 and 222 to glutamic acid for an activating mutation or to alanine for an interfering mutation (Cowley et al., 1994) . They found that expression of activated MEK-1 resulted in neuronal dierentiation of PC12 cells and transformation of NIH3T3 cells. On the other hand, interfering mutants of MEK-1 caused inhibition of growth factor induced PC12 dierentiation and proliferation, as well as morphological reversion in c-src and ras-transformed cells. Similar results were also reported by Brunet et al. (1994) when they expressed constitutively activated MEK-1 mutant in Chinese hamster lung ®broblasts. These studies strongly support the idea that MEKs play a central role in cell signaling and transformation, and activating mutants of MEK genes can act as dominant oncogenes. However, search for mutations in MEK genes in naturally occurring human tumors has not yet been reported. To study the role of MEK genes in the pathogenesis of lung cancer, we have analysed the entire coding sequences of MEK-1 and MEK-2 cDNAs in several human lung cancer cell lines for mutations using single strand conformation polymorphism (SSCP) analysis and DNA sequencing. We ®nd that mutations altering the amino acid sequence of MEK-1 or MEK-2 gene in human lung cancer are rare events.
Results
To test for the presence of mutations in the MEK-1 (GenBank accession #L11284) and MEK-2 (GenBank accession #L11285) genes, we evaluated the open reading frames of RT ± PCR cDNA products of both genes by SSCP analysis using seven pairs of overlapping primers for each gene to optimize SSCP sensitivity (Table 1) . cDNAs from thirty seven lung cancer cell lines were studied including 16 small cell lung cancers (SCLC), 18 non-small cell lung cancers (NSCLC), one mesothelioma, one carcinoid, and one extrapulmonary small cell cancer (see Methods). The ras mutation (k-, H-and N-ras) status has been reported for these lung cancer lines and 0/19 SCLC and 6/18 NSCLC had a K-ras mutation (see Methods for lines with ras mutations) with no H-or N-ras mutations found (Mitsudomi et al., 1991) . In addition, thirteen B-lymphoblastoid (BL) cell lines that came from some of the patients donating tumor cell lines were also studied.
Primer pair MEK-2.11 and MEK-2.12 showed an SSCP abnormality in one NSCLC cell line, H647, where nt 977 was mutated from C to T resulting in amino acid 298 change from proline to leucine ( Figure  1 ). Of interest, this NSCLC also had a K-ras mutation (K-ras 13 Gly to Cys) (Mitsudomi et al., 1991) .
The primer pair MEK-2.9 and MEK-2.10, amplifying the region between nucleotides 677 and 842 of MEK-2 cDNA detected a common SSCP alteration in MEK-2 cDNA ( Figure 2 ). DNA sequence analysis of this region revealed that the SSCP alteration resulted from an A to C substitution at nt 744 (codon 220 ATA to ATC) that did not alter the amino acid sequence (data not shown). In 13 BL lines the expression of the MEK-2 nt 744 polymorphism was: both A and C forms expressed in six lines; only A form expressed in three lines and only C form expressed in three; with one BL line not expressing MEK-2 cDNA. The frequency of expression of the two alleles in BL lines was exactly that predicted by the Hardy ± Weinberg distribution and gives an allele frequency of 0.5 for A and 0.5 for C. The 37 lung cancer lines, however, had a dierent frequency of expression of the two alleles: expression of A/C was found in six, only A in nine and only C in 22 lines. By chi square analysis this dierence was signi®cant (w 2 =6.334, P=0.0421). Six of the BL lines (BL1395, BL1437, BL1648, BL1993, BL2052, BL2171) expressed both the A and the C forms (were heterozygous) but only mesothelioma line H2052 of the corresponding matched tumor cell lines expressed both the A and the C forms. This suggested there was either loss of heterozygosity of MEK-2 or selective expression of only one allele of MEK-2 occurring in the lung cancer cell lines.
Finally, primer pair MEK-2.5 and MEK-2.6 amplifying the region between nt 356 and 561 of MEK-2 cDNA showed a SSCP shift in NSCLC H2009 and in the B lymphoblastoid cell line BL2009. Sequence analysis revealed nucleotide 537 changed from C to T, (data not shown), a mutation that did not alter the amino acid sequence suggesting the presence of a rare polymorphism.
SSCP analysis of MEK-1 cDNA revealed only one migration pattern change in SCLC line H1672 cDNA which was also present in the cDNA from the corresponding BL cell line (BL1672) (Figure 3 ). DNA sequencing showed the SSCP alteration resulted from a G to A substitution at nt 783 that resulted in no amino acid change. Comparison of SCLC H1672 cDNA with 
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Discussion
Several members of the MAP kinase pathway are oncogene products (such as Ras, Raf-1 and Mos), and overexpression or point mutations in these genes can result in cellular transformation and upstream activation of MEKs. In addition, introduction by in vitro mutagenesis of point mutations in MEK-1 in the two functionally important serine residues (218 and 222) within the catalytic domain, results in a constitutively active kinase which has cellular transforming and oncogenic properties in mammalian systems (Brunet et al., 1994; Cowley et al., 1994; Mansour et al., 1994) . However, no naturally occurring mutations in MEK genes in any malignant tissues have yet been described. For this reason we undertook the studies reported here.
We studied the expression and tested for the presence of mutations in the open reading frame of MEK-1 and MEK-2 cDNAs in a large panel of 37 human cancer lines representing all histologic types of pulmonary malignancies. RT ± PCR analysis showed that all the cell lines tested expressed both MEK-1 and MEK-2 mRNAs. We found a common polymorphism in MEK-2 (nt 744 A/C) and rare nucleotide polymorphisms in MEK-1 (nt 783 G/A) and MEK-2 (nt 537 C/T) which did not alter the amino acid sequences. Of interest, the MEK-2 nt 744 A/C common polymorphism showed loss of heterozygous expression in 5/6 lung cancers heterozygous for this locus. The most likely explanation for this allele loss of the region where the MEK-2 gene resides. Currently, the MEK-2 gene has not been mapped to a human chromosome.
We only found one amino acid alteration in MEK-2 (nt 977 C to T leading to Pro 298 to Leu substitution) in one NSCLC. Thus, our data show that MEK-1 and MEK-2 cDNAs had only a rare or no mutations in human lung cancers suggesting that these genes are not targets for genetic alterations in human lung cancer development. The possibility of mutations of the MEK genes in other types of human cancers remains to be studied.
The MAP kinase pathway could still be involved in lung cancer pathogenesis. Approximately 30% of NSCLCs have mutations in K-ras gene, an upstream activator of the MAP kinase (Mitsudomi et al., 1991) ; and SCLC lines frequently show deranged expression of myc gene family, downstream eector of the ERKs (Krystal et al., 1988; Little et al., 1983; Nau et al., 1985 Nau et al., , 1986 . It is also possible that activation of other components of the pathways such as the ERKs, phosphatases, or proto-oncogene c-raf through genetic mutation in lung tumors can lead to activation of the pathway. Thus, future studies involving regulation of the MAP kinase pathway and analysis of other members of the kinase will be needed.
Materials and methods

Cell lines
The lung cancer cell lines used in this study have been deposited by us in the American Type Culture Collection (Rockville, MD). Cell lines designated BL are normal EB virus transformed B-lymphoblastoid cell lines, established from the blood of the corresponding tumor patients (e.g. BL1184 was from the patient donating tumor cell line NCI-H1184). Cell lines were grown in medium RPMI-1640 supplemented with 5% fetal calf serum and antibiotics. Total of 50 cell lines were used in this study. Thirteen Blymphoblastoid cell lines were: BL1184 (BL5), BL1339 (BL6), BL1395, BL1437, BL1648 (BL10), BL1672, BL1770, BL1993, BL2009, BL2052, BL2087, BL2107, BL2171. Eighteen non-small cell lung cancer lines were: NCI-H322, H324, H522, H647, H1334, H1385, H1395, H1437, H1466, H1648, H1650, H1770, H1792, H1944, H1993, H2009, H2087, H2122. Sixteen small cell lung cancer lines were: NCI-H82, H209, H524, H526, H711, H841, H1045, H1092, H1184, H1339, H1672, H1788, H1876, H2081, H2107, H2171. Three, other pulmonary malignancies were cell lines: NCI-H720, carcinoid; H1048, extrapulmonary small cell like tumor; H2052, mesothelioma. The 37 cancer cell lines, had been typed for H, N and K-ras mutations in a previous study and six of the tumors, all NSCLCs, had a K-ras mutation (Mitsudomi et al., 1991) . These were H1385 (K-ras 12 Gly to Cys), H1792 (K-ras 12 Gly to Cys), H2122 (K-ras 12 Gly to Cys), H2009 (K-ras 12 Gly to Ala), H647 (K-ras 13 Gly to Asp), H1944 (K-ras 13 Gly to Asp).
cDNA PCR/SSCP and sequencing analysis
Random primed cDNA was prepared from total RNA, RT ± PCR, and single strand conformation polymorphism (SSCP) analysis were performed using standard methods (Sekido et al., , 1995 . Primers (summarized in Table  1 ) were designed to amplify published coding sequences of MEK-1 (GenBank accession # L11284) and MEK-2 (GenBank accession # L11285) cDNAs (Zheng and Guan, 1993) . Prior to SSCP analysis, PCR conditions for each primer pair were optimized. cDNA fragments spanning the open reading frames of MEK-1 and MEK-2 were PCR ampli®ed using 0.5 mg of random primed cDNA as templates, 1 mM of each primer and 1 mCi [a-32 P]dCTP (53000 Ci/mmol; Amersham) in 10 ml reaction volume in the Perkin Elmer Cetus thermocycler model 9600. The PCR products were diluted 1 : 3 with loading formamide buer and denatured at 958C for 5 min. Three ml of these samples were electrophoretically separated on a MDE gel (JT Baker, NJ) for 16 h at 2 ± 3 watts at room temperature and in some cases at 48C. The gels were subsequently dried and autoradiographed. SSCP abnormalities were con®rmed by direct DNA sequencing. Direct sequencing was performed using Sequenase PCR product sequencing kit with [ 35 S]dATP, as per manufacturer's guidelines (USB, Ohio). For heterozygous samples, the abnormal bands were cut out from the SSCP gel and the DNA was eluted by incubating the band in 100 ml deionized water at 378C for 1 h. The eluted DNA was further PCR ampli®ed using one biotinylated primer in order to isolate single-stranded DNA using streptavidin-coated magnetic beads (Dynabeads, Dynal, Norway). This DNA was sequenced using Sequenase version 2 kit (USB, Ohio) as per manufacturer's protocol.
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